Arecor Therapeutics PLCLSE: AREC

Arecor 2021 annual report and notice of AGM

· Issued by Arecor Therapeutics PLC
RNS Number : 5943J
Arecor Therapeutics PLC
27 April 2022

Arecor Therapeutics plc

("Arecor" or the "Group")

POSTING OF ARECOR 2021 ANNUAL REPORT AND NOTICE OF AGM

Cambridge , UK, 27 April 2022. Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives, announces that it has today published and posted to shareholders the Annual Report and Accounts for the year ended 31 December 2021 and Notice of the Annual General Meeting ("AGM") which will be held at Covington & Burling LLP, 22 Bishopsgate, London EC2N 4BQ , on 23 May 2022 at 1.00 p.m. (BST).

The Annual Report and Accounts and notice of AGM are also available to view on, and download from, the Company's website at www.arecor.com/investor-centre/ .

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR)

-ENDS-

For more information, please contact:

Arecor Therapeutics plc

www.arecor.com

Dr Sarah Howell, Chief Executive Officer

Tel: +44 (0) 1223 426060

Email: [email protected]

Susan Lowther, Chief Financial Officer

Tel: +44 (0) 1223 426060

Email: [email protected]

Mo Noonan, Communications

Tel: +44 (0) 7876 444977

Email: [email protected]

Panmure Gordon (UK) Limited (NOMAD and Broker)

Freddy Crossley, Emma Earl (Corporate Finance)

Rupert Dearden (Corporate Broking)

Tel: +44 (0) 20 7886 2500

Consilium Strategic Communications

Chris Gardner, David Daley, Angela Gray

Tel: +44 (0) 20 3709 5700

Email: [email protected]

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.

For further details please see our website, www.arecor.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END
MSCSEIFMWEESESL

Arecor Therapeutics PLC on 6ix

Earlier from Arecor Therapeutics

Later from Arecor Therapeutics

All Arecor Therapeutics news releases